i'm in, page-5

me to , love Neu if it gets to 10c .

from presentation in 2011 for those who are Neu

Market potential on NNZ-2566
•
1.5 million brain injuries per year in the US alone
•
No approved therapies
•
Assuming $12,000 for IV and $3,000 for oral as price point, total potential market value is:
•
Moderate –severe = ~$2 billion
•
Mild = ~$2 billion
•
~$500 million peak annual sales forecast (15% market penetration; hospitalized and emergency department patients only)
Competitive advantages
•
Only product to address the full range of TBI from mild to severe
•
Only competitive product currently in Phase II or beyond is progesterone
•
Two approvable outcomes: neurological function andprevention of seizures
•
Mechanism reflects broad pharmacologic actions of a naturally occurring product
•
Excellent safety profile: few serious adverse events and no known or expected drug interactions
•
Key opinion leaders (KOLs) already involved and committed
Partnership opportunities
•
US Army financing development; will be a major client (no residual rights)
•
Partnership opportunities in multiple fields and indications for oral and intravenous



Intravenous administration

TBI (moderate to severe)*
Stroke
Cardiac arrest
Perinatalasphyxia
Penetrating brain injury
Non-convulsive seizures in other CNS injuries/conditions

Oral administration

Mild TBI*
RettSyndrome/other autism spectrum disorders*
Post-stroke recovery
Prophylaxis following transient ischemic attack
Chemotherapy-induced neuropathy



Market potential of Motiva

Market potential for apathy in selected indications
16
Stroke: $1,248,000,0001
Traumatic brain injury: $840,000,000
Parkinson’s disease: $1,056,000,000
1 Assumes reimbursement at $2,400 per year
Peak annual sales forecast2(10% market penetration): ~$280 million


RettSyndrome
•
Largest single cause of intellectual disability and autism in females;
genetic disorder caused by a mutation in the MECP2gene
•
Normal infant development followed by loss of language, social contact
and motor functions, epilepsy
•
Large market potential –US = $430 million; global = $1.2 billion

http://www.stocknessmonster.com/news-item?S=NEU&E=ASX&N=641987

http://ausbiotech2011.com.au/uploads/Neuren.pdf